Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy

Cancer remains a leading cause of death worldwide. Despite many signs of progress, currently available cancer treatments often do not provide desired outcomes for too many cancers. Therefore, newer and more effective therapeutic approaches are needed. Oncolytic viruses (OVs) have emerged as a novel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masmudur M. Rahman, Grant McFadden
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	oncolytic virus immunotherapy cancer therapy combination therapy oncolytic virotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/40fca3f2a9bb450a95a1daf95c759442
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40fca3f2a9bb450a95a1daf95c759442
record_format	dspace
spelling	oai:doaj.org-article:40fca3f2a9bb450a95a1daf95c7594422021-11-11T15:33:28ZOncolytic Viruses: Newest Frontier for Cancer Immunotherapy10.3390/cancers132154522072-6694https://doaj.org/article/40fca3f2a9bb450a95a1daf95c7594422021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5452https://doaj.org/toc/2072-6694Cancer remains a leading cause of death worldwide. Despite many signs of progress, currently available cancer treatments often do not provide desired outcomes for too many cancers. Therefore, newer and more effective therapeutic approaches are needed. Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, which selectively targets and kills cancer cells while sparing normal ones. In the past several decades, many different OV candidates have been developed and tested in both laboratory settings as well as in cancer patient clinical trials. Many approaches have been taken to overcome the limitations of OVs, including engineering OVs to selectively activate anti-tumor immune responses. However, newer approaches like the combination of OVs with current immunotherapies to convert “immune-cold” tumors to “immune-hot” will almost certainly improve the potency of OVs. Here, we discuss strategies that are explored to further improve oncolytic virotherapy.Masmudur M. RahmanGrant McFaddenMDPI AGarticleoncolytic virusimmunotherapycancer therapycombination therapyoncolyticvirotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5452, p 5452 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	oncolytic virus immunotherapy cancer therapy combination therapy oncolytic virotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	oncolytic virus immunotherapy cancer therapy combination therapy oncolytic virotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Masmudur M. Rahman Grant McFadden Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
description	Cancer remains a leading cause of death worldwide. Despite many signs of progress, currently available cancer treatments often do not provide desired outcomes for too many cancers. Therefore, newer and more effective therapeutic approaches are needed. Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, which selectively targets and kills cancer cells while sparing normal ones. In the past several decades, many different OV candidates have been developed and tested in both laboratory settings as well as in cancer patient clinical trials. Many approaches have been taken to overcome the limitations of OVs, including engineering OVs to selectively activate anti-tumor immune responses. However, newer approaches like the combination of OVs with current immunotherapies to convert “immune-cold” tumors to “immune-hot” will almost certainly improve the potency of OVs. Here, we discuss strategies that are explored to further improve oncolytic virotherapy.
format	article
author	Masmudur M. Rahman Grant McFadden
author_facet	Masmudur M. Rahman Grant McFadden
author_sort	Masmudur M. Rahman
title	Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
title_short	Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
title_full	Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
title_fullStr	Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
title_full_unstemmed	Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
title_sort	oncolytic viruses: newest frontier for cancer immunotherapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/40fca3f2a9bb450a95a1daf95c759442
work_keys_str_mv	AT masmudurmrahman oncolyticvirusesnewestfrontierforcancerimmunotherapy AT grantmcfadden oncolyticvirusesnewestfrontierforcancerimmunotherapy
_version_	1718435233944043520

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy

Ejemplares similares